Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects

• DOI: 10.1111/dme.12231
• Publication Date: 2013-05-11T11:12:38Z
• Authors: F. K. Knop; E. Konings; S. Timmers; P. Schrauwen; J. J. Holst; E. E. Blaak
• Keywords: Incretin; Crossover study; Gastric inhibitory polypeptide

Resveratrol, a natural polyphenolic compound produced by various plants (e.g. red grapes) and found in wine, has glucose-lowering effects humans rodent models of obesity and/or diabetes. The mechanisms behind these have been suggested to include resveratrol-induced secretion the gut incretin hormone glucagon-like peptide-1. We investigated postprandial glucagon responses obese human subjects before after 30 days resveratrol supplementation.Postprandial plasma hormones peptide-1 glucose-dependent insulinotropic polypeptide were evaluated 10 men [subjects characteristics (mean ± standard error mean): age 52 2 years; BMI 32 1 kg/m(2), fasting glucose 5.5 0.1 mmol/l] who had given dietary supplement (Resvida(®) 150 mg/day) or placebo for randomized, double-blind, crossover design with 4-week washout period. At end each intervention period standardized meal test (without co-administration resveratrol) was performed.Resveratrol supplementation no impact on concentrations (area under curve values) (11.2 2.1 vs. 11.8 2.2 pmol/l, P = 0.87; 17.0 14.8 1.6 min × nmol/l, 0.20) (15.4 1.0 15.2 0.9 0.84; 5.6 0.4 5.7 0.3 0.73). Resveratrol significantly suppressed (4.4 3.9 0.01) without affecting levels (15.2 14.5 1.5 0.56).Our data suggest that does not affect humans, but suppresses responses.